


PHARMACEUTICAL 2018

LANDEC CORP \CA\ Rank 37 of 349







RealRate

PHARMACEUTICAL 2018

LANDEC CORP \CA\ Rank 37 of 349



The relative strengths and weaknesses of LANDEC CORP \CA\ are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LANDEC CORP \CA\ compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 813% points. The greatest weakness of LANDEC CORP \CA\ is the variable Other Expenses, reducing the Economic Capital Ratio by 596% points.

The company's Economic Capital Ratio, given in the ranking table, is 121%, being 398% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	81,280
Cost of Goods Sold	0
Intangible Assets	54,779
Liabilities, Current	51,454
Liabilities, Non-Current	42,299
Other Assets	89,329
Other Compr. Net Income	345
Other Expenses	457,812
Other Liabilities	36,703
Other Net Income	1,333
Property and Equipment	133,220
Research and Development	9,473
Revenues	532,257
Selling, General and Administrative Expense	55,628

Output Variable	Value in 1000 USD
Assets	358,608
Liabilities	130,456
Expenses	522,913
Stockholders Equity	228,152
Net Income	10,677
Comprehensive Net Income	10,850
Economic Capital Ratio	121%

